low - Healthcare utilization for cancer diagnostics is largely non-discretionary and driven by disease incidence rather than economic conditions. Prostate cancer screening and staging procedures continue regardless of GDP growth, though hospital capital equipment budgets for PET scanners may be modestly affected during severe recessions. Medicare/insurance reimbursement provides revenue stability.

Moderate sensitivity through two channels: (1) Lantheus carries $275M in debt (0.55 D/E ratio), so rising rates increase interest expense modestly, though operating cash flow of $500M provides ample coverage; (2) As a growth stock trading at 3.3x sales, valuation multiples compress when risk-free rates rise and investors rotate from growth to value. The 10-year Treasury yield affects discount rates applied to future cash flows from pipeline assets.

growth - Investors are attracted to PYLARIFY's 30-40% annual growth trajectory in an expanding prostate cancer diagnostics market, with potential upside from therapeutic pipeline optionality. The stock appeals to healthcare-focused growth funds and biotech specialists willing to accept binary clinical trial risk. Recent 38% three-month return reflects momentum following strong commercial execution, though -10% one-year return indicates volatility around pipeline milestones and competitive concerns.